Delcath Systems (DCTH) Received its Third Buy in a Row

Markets
After Canaccord Genuity and Roth Capital gave Delcath Systems (NASDAQ: DCTH) a Buy rating last month, the company received another Buy, this time from BTIG. Analyst Marie Thibault reiterated a Buy rating on Delcath Systems today and set a price target of $23.00. The company’s shares closed last Monday at $11.57.
According to TipRanks.com, Thibault is a 5-star analyst with an average return of 74.1% and a 61.5% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Irhythm Technologies.
Currently, the analyst consensus on Delcath Systems is a Strong Buy with an average price target of $24.00.

Related Keywords

New York ,United States ,Canaccord Genuity ,Marie Thibault ,Edwards Lifesciences ,Establishment Labs Holdings ,Delcath Systems Inc ,After Canaccord Genuity ,Roth Capital ,Delcath Systems ,Strong Buy ,Melphalan Hydrochloride ,Delcath Hepatic Delivery ,புதியது யார்க் ,ஒன்றுபட்டது மாநிலங்களில் ,கானக்கோர்ட் உண்மையானது ,மேரி திபோுல்ட் ,எட்வர்ட்ஸ் ஆயுள் அறிவியல் ,ஸ்தாபனம் ஆய்வகங்கள் ஹோல்டிங்ஸ் ,ரோத் மூலதனம் ,வலுவான வாங்க ,